Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by dexiieeon Jan 07, 2021 12:22pm

162 Views

Post# 32242709

Sponsored Post: Prestige Category

The following closely behind food products are the similarly sized hemp-derived CBD beauty products and pet-products segments. There simply isn’t enough research to conclude that adding CBD to beauty products has significant health benefits. Instead, many of the benefits may come from other ingredients. That's a great read, very insightful! Want more information?

Manufacturers focused on getting CBD approved as a food ingredient but the food category is one of the smallest CBD segment. On the other hand, the prestige category, which includes beauty and skin care products typically available from higher-end retailers, might offer greater chance both in the short term and the future as trades are expected to increase approximately 1,000% in the next five years.

CBD beauty products are projected to reach approximately $191 million in 2020, with estimated 7% growth to $507 million by 2025. Likewise, the hemp-CBD pet products market, estimated at $191 million in sales this year, is projected to grow 7% in five years to $506 million. Check the disclaimer on the profile and landing page.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading